Outcomes of the Pediatric Development Plan of Tapentadol

References

• Eerdekens M, Beuter C, Lefeber C, van den Anker J.The challenge of developing pain medications for children: therapeutic needs and future perspectives. J Pain Res. 2019;12:1649–1664. doi:10.2147/JPR.S195788
   PubMed Web of Science ®Google Scholar
• Grégoire MC, Finley GA. Drugs for chronic pain in children: a commentary on clinical practice and the absence of evidence. Pain Res Manag. 2013;18(1):47–50. doi:10.1155/2013/402863
   Web of Science ®Google Scholar
• Califf RM Best Pharmaceuticals for Children Act and Pediatric Research Equity Act Status Report to Congress; 2016. Available from: https://www.fda.gov/downloads/scienceresearch/specialtopics/pediatrictherapeuticsresearch/ucm509815.pdf. Accessed September 8, 2020.
   Google Scholar
• European Union. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use, OJ L 378, 27.12;.2006. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. Accessed September 8, 2020.
   Google Scholar
• Nafziger AN, Barkin RL. Opioid therapy in acute and chronic pain. J Clin Pharmacol. 2018;58(9):1111–1122. doi:10.1002/jcph.1276
   PubMed Web of Science ®Google Scholar
• Xiao JP, Li AL, Feng BM, Ye Y, Wang GJ. Efficacy and safety of tapentadol immediate release assessment in treatment of moderate to severe pain: a systematic review and meta-analysis. Pain Med. 2017;18(1):14–24. doi:10.1093/pm/pnw154
   PubMed Web of Science ®Google Scholar
• Viscusi E, Allard R, Sohns M, Eerdekens M. Tapentadol immediate release for moderate to severe acute post-surgery pain. J Opioid Manag. 2019;15:51–67. doi:10.5055/jom.2019.0486
   Google Scholar
• Baron R, Eberhart L, Kern KU, et al. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract. 2017;17:678–700. doi:10.1111/papr.12515
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs. 2014;28:319–329. doi:10.1007/s40263-014-0151-9
   PubMed Web of Science ®Google Scholar
• Raffa RB, Elling C, Tzschentke TM. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘µ-load’. Adv Ther. 2018;35:1471–1484. doi:10.1007/s12325-018-0778-x
   PubMed Web of Science ®Google Scholar
• Göhler K, Brett M, Smit JW, Rengelshausen J, Terlinden R. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther. 2013;51(4):338–348. doi:10.5414/CP201722
   PubMed Web of Science ®Google Scholar
• Terlinden R, Kogel BY, Englberger W, Tzschentke TM. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol. 2010;32:31–38. doi:10.1358/mf.2010.32.1.1434165
   PubMedGoogle Scholar
• Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future. 2006;31:1053–1061.
   Web of Science ®Google Scholar
• Kneip C, Terlinden R, Beier H, Chen G. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008;2:67–75. doi:10.2174/187231208783478434
   PubMedGoogle Scholar
• Smit JW, Oh C, Rengelshausen J, et al. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy. 2010;30:25–34. doi:10.1592/phco.30.1.25
   PubMed Web of Science ®Google Scholar
• Watson E, Khandelwal A, Freijer J, van den Anker J, Lefeber C, Eerdekens M. Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population. J Pain Res. 2019;12:2835–2850. doi:10.2147/JPR.S208454
   Web of Science ®Google Scholar
• Khalil F, Choi SL, Watson E, et al. Population pharmacokinetics of tapentadol in children from birth to <18 years old. J Pain Res. 2020;13:3107–3123. doi:10.2147/JPR.S269549
   Web of Science ®Google Scholar
• Finkel J, Goldberg J, Rosenburg R, et al. First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18. J Pain Res. 2019;12:1925–1936. doi:10.2147/JPR.S197348
   PubMed Web of Science ®Google Scholar
• Muse D, Tarau E, Lefeber C, et al. Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients. J Pain Res. 2019;12:1777–1790. doi:10.2147/JPR.S197039
   PubMed Web of Science ®Google Scholar
• Eissa A, Tarau E, Beuter C, et al. Tapentadol for the treatment of moderate-to-severe acute pain in children under the age of two years. J Pain Res. 2021;14:229-248.
   Web of Science ®Google Scholar
• Beuter C, Volkers G, Radic T, Goldberg J, van den Anker J. Efficacy and safety of multiple doses of tapentadol oral solution in the treatment of moderate to severe acute pain in children aged 2 to <18 years - a randomized, double-blind, placebo-controlled trial. J Pain Res. 2019;12:3099–3112. doi:10.2147/JPR.S207010
   Web of Science ®Google Scholar
• Electronic Medicines Compendium. Palexia oral solution 20 mg/mL. Available from: https://www.medicines.org.uk/emc/product/5346/smpc. Accessed September 4, 2020.
   Google Scholar
• Howard R, Radic T, Sohns M, Eerdekens M, Waßmuth A. Tapentadol prolonged release for long-term treatment of pain in children. J Pain Res. 2020;13:3157–3170. doi:10.2147/JPR.S272751
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. CDER conversations: pediatric pain management options. Available from: https://www.fda.gov/drugs/news-events-human-drugs/cder-conversation-pediatric-pain-management-options. Accessed December 30, 2019.
   Google Scholar
• Electronic Medicines Compendium. Palexia 50 mg film-coated tablets. Available from: https://www.medicines.org.uk/emc/medicine/28375. Accessed September 7, 2020.
   Google Scholar
• Electronic Medicines Compendium. Palexia SR prolonged release tablets. Summary of product characteristics. Available from: https://www.medicines.org.uk/emc/medicine/28373. Accessed September 7, 2020.
   Google Scholar
• Health Products Regulatory Authority. Palexia 4 mg/mL oral solution. Available from: https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2242-012-010_04032020131343.pdf. Accessed September 7, 2020.
   Google Scholar
• Khandelwal A, Bolger M, Brett M, Rosenburg R, Bursi R Physiologically-based pharmacokinetic (PBPK) model of tapentadol and tapentadol-O-glucuronide in adult and pediatric population. Available from: http://www.pkuk.org.uk/Contentimages/PKUK_2014_Programme_and_Abstractsnew.pdf. Accessed January 04, 2021.
   Google Scholar
• Hlavin G, Koenig F, Male C, Posch M, Bauer P. Evidence, eminence and extrapolation. Stat Med. 2016;35(13):2117–2132. doi:10.1002/sim.6865
   Web of Science ®Google Scholar
• European Medicines Agency. Reflection paper on the use of extrapolation in the development of medicines for paediatrics. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/adopted-reflection-paper-use-extrapolation-development-medicines-paediatrics-revision-1_en.pdf. Accessed September 7, 2020.
   Google Scholar
• Hosseini Jahromi SA, Hosseini Valami SM, Hatamian S. Comparison between effect of lidocaine, morphine and ketamine spray on post-tonsillectomy pain in children. Anesth Pain Med. 2012;2:17–21. doi:10.5812/aapm.4092
   Google Scholar
• Urquhart E. Analgesic agents and strategies in the dental pain model. J Dent. 1994;22:336–341. doi:10.1016/0300-5712(94)90084-1
   PubMed Web of Science ®Google Scholar
• Berde CB, Walco GA, Krane EJ, et al. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics. 2012;129(2):354–364. doi:10.1542/peds.2010-3591
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 10-year report to the European Commission - general report on the experience acquired as a result of the application of the Paediatric Regulation. Available from: https://ec.europa.eu/health/sites/health/files/files/paediatrics/docs/paediatrics_10_years_ema_technical_report.pdf. Accessed September 7, 2020.
   Google Scholar
• European Medicines Agency. European Medicines Agency and European Commission (DG Health and Food Safety) action plan on paediatrics. Available from: https://www.ema.europa.eu/en/documents/report/european-medicines-agency-european-commission-dg-health-food-safety-action-plan-paediatrics_en.pdf. Accessed September 8, 2020.
   Google Scholar
• Zannikos PN, Smit JW, Stahlberg HJ, Wenge B, Hillewaert VM, Etropolski MS. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects. J Opioid Manag. 2013;9(4):291–300. doi:10.5055/jom.2013.0171
   Google Scholar